Sensing Cancer on a Nanoscale Level
Cellens is a Boston-based Tufts University spinout pioneering a non-invasive cancer diagnostics platform that uses nanoscale mechanobiology and machine learning to detect bladder cancer from urine samples. Its Octosense platform scans cell surfaces at nanoscale resolution to identify unique biophysical fingerprints of cancer cells. The company raised a $6.5M seed round in December 2025 to advance its AI-driven diagnostic technology.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account